Browse News
Filter News
Found 42 articles
-
Remix Therapeutics to Present at Jefferies Healthcare Conference
5/25/2023
Remix Therapeutics (Remix) today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 12:30 p.m. ET in New York.
-
Remix Therapeutics Appoints Robert Gagnon as Chief Financial Officer
3/22/2023
Remix Therapeutics today announced the appointment of Robert Gagnon as Chief Financial Officer.
-
Remix Therapeutics Appoints Christopher Bowden, M.D., as Chief Medical Officer
1/5/2023
Remix Therapeutics, a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, announced the appointment of Christopher Bowden, M.D., as Chief Medical Officer.
-
CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development
12/19/2022
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023.
-
Remix Therapeutics to Present at 5th Annual RNA-Targeted Drug Discovery Summit
12/8/2022
Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies to modulate RNA processing and address the underlying drivers of disease, today announced that executive management will present at the 5th Annual RNA-Targeted Drug Discovery Summit to be held December 14-15, 2022 in Boston.
-
Nested Therapeutics Launches With $125 Million Financing
10/6/2022
Nested Therapeutics announced the completion of a $90 million Series A financing led by the Life Sciences Investing business within Goldman Sachs Asset Management, bringing the total financing to $125 million since Versant Ventures founded the company.
-
Agilent Announces New Revolutionary Quadrupole Mass Spectrometers at ASMS 2022
6/6/2022
Agilent Technologies Inc. (NYSE: A) today announced new LC/MS and GC/MS quadrupole mass spectrometers which will be on show at the 70th ASMS Conference on Mass Spectrometry and Allied Topics being held June 5 - 9, 2022 in Minneapolis, Minnesota.
-
Remix Therapeutics to Present at Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Remix Therapeutics announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix, will present a corporate overview at the Jefferies Healthcare Conference on Wednesday, June 8, 2022, at 4:30 p.m. ET in New York.
-
Recent funding saw support for a platform that selectively degrades DNA, software to help read mammograms and a company using corn genetics to develop cancer-targeting viruses.
-
Civetta Therapeutics Appoints Jesse Smith, Ph.D. as CSO and Susan Ashwell, Ph.D. as SVP of Chemistry
5/17/2022
Civetta Therapeutics, LLC, a biotechnology company focused on developing a pipeline of therapies that target beta-propeller proteins, today announced that it has strengthened its management team with the additions of Jesse Smith, Ph.D., as Chief Scientific Officer and Susan Ashwell, Ph.D., as SVP of Chemistry.
-
Remix Therapeutics Closes $70 Million Series B Financing
5/17/2022
Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, announced the close of a $70 million Series B financing.
-
Remix Therapeutics Announces Publication on Reprogramming RNA Processing
3/30/2022
Remix Therapeutics today announced the publication of an article titled "Reprogramming RNA Processing: An Emerging Therapeutic Landscape," in the peer-reviewed journal Trends in Pharmacological Sciences.
-
Remix Therapeutics to Participate in SVB Leerink Biopharma Private Company Connect
3/24/2022
Remix Therapeutics, a biotechnology company developing small molecule therapies designed to modulate RNA processing and address the underlying drivers of disease, announced that management will participate in one-on-one meetings with investors at the SVB Leerink Biopharma Private Company Connect being held virtually from March 29-31, 2022.
-
Remix Therapeutics to Present at RNA Leaders World Congress
3/16/2022
Remix Therapeutics announced an upcoming presentation at the RNA Leaders World Congress taking place March 16-17, 2022 in Basel, Switzerland.
-
The strategic collaboration centers on Remix’s REMaster platform for the discovery and development of small molecule therapies that modulate RNA processing.
-
Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing
2/17/2022
Remix Therapeutics today announced a strategic collaboration with Janssen Pharmaceutica NV for the discovery and development of small molecule therapeutics that modulate RNA processing using Remix's REMaster drug discovery platform.
-
BioSpace Movers & Shakers, Dec. 17
12/17/2021
As 2021 moves closer to its end, biopharma and life sciences companies from across the globe continue to strengthen their leadership teams and boards with these Movers & Shakers. -
Remix Therapeutics Appoints Zaven Kaprielian, Ph.D., as Chief Scientific Officer
12/15/2021
Remix Therapeutics, a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, announced the appointment of Zaven Kaprielian, Ph.D., as Chief Scientific Officer.
-
Remix Therapeutics to Present at 4th Annual RNA-Targeted Drug Discovery Summit
12/6/2021
Remix Therapeutics today announced that Peter Smith, Ph.D., Co-Founder and Chief Executive Officer of Remix Therapeutics, will deliver a presentation highlighting the Company’s approaches to modulating RNA processing with small molecules at the 4th Annual RNA-Targeted Drug Discovery Summit.
-
BioSpace Movers & Shakers, Aug. 20
8/20/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.